Key Development
UCB’s Bimzelx became the highest-spending pharmaceutical brand in U.S. cross-platform television advertising in September 2026, with an estimated US$56.9 million in spending. More important than the ranking itself, however, is where the money went: approximately 53.85% was allocated to streaming and 46.15% to traditional linear television.
That marks a sharp acceleration from August, when Bimzelx first reached the top of iSpot’s pharma advertising ranking with roughly US31.5millioninlinear-TVspending.September’sbudgetwasdistributedacrosspsoriasis,psoriaticarthritisandhidradenitissuppurativacampaigns,atapproximatelyUS24.9 million, US16.7millionandUS15.3 million respectively.
The advertising push coincides with rapid commercial scaling. UCB reported approximately €1.53 billion of Bimzelx net sales in the first half of 2026, up 91% year over year, with more than 135,000 patients treated globally. The company has raised peak-sales guidance to at least €7 billion.
Why It Matters
- UCB is buying commercial acceleration, not simply awareness.
- Streaming is becoming a core DTC pharmaceutical channel, not an experimental extension of television.
- Multi-indication brands create stronger marketing economics, because customer acquisition can support several disease markets.
- Commercial execution is increasingly as important as clinical differentiation in crowded specialty-drug categories.
Healthcare Insight Analysis
Healthcare Insight believes Bimzelx is entering the stage where clinical differentiation must be converted into commercial velocity.
Bimekizumab’s dual inhibition of IL-17A and IL-17F gives UCB a differentiated scientific story. But in immunology, strong efficacy data alone do not guarantee prescription growth.
Patients need awareness.
Physicians need brand familiarity.
Payers need to provide access.
Patients then need to initiate and remain on therapy.
Advertising is therefore increasingly part of launch infrastructure, rather than simply a promotional expense.
Streaming makes that infrastructure more sophisticated.
Traditional TV provides scale. Streaming can offer more precise audience targeting, frequency management and potentially richer measurement of downstream engagement.
Bimzelx’s September allocation illustrates this shift.
The psoriasis campaign still leaned more toward linear television, while roughly 68% of PsA spending and 61% of HS spending went to streaming.
That suggests an emerging commercial logic:
large disease population → broad reach
more defined disease population → targeted streaming
For specialty pharma, this could become a repeatable model.
However, advertising leadership is not the same as market leadership.
Bimzelx competes against deeply established brands including Skyrizi, Rinvoq and Tremfya, which benefit from physician familiarity, payer contracts and large installed patient bases.
Media can create demand, but the economic value of that demand disappears if patients encounter prior authorization barriers, formulary restrictions or low switching propensity.
The correct KPI is therefore not share of voice.
It is:
media exposure → patient inquiry → physician conversation → prescription → payer approval → persistence.
Only if conversion improves across this full funnel does US$56.9 million represent productive growth investment.
Bimzelx’s expanding indication architecture also matters. In the U.S., it is approved across plaque psoriasis, psoriatic arthritis, axial spondyloarthritis and hidradenitis suppurativa.
This allows UCB to build a single immunology masterbrand across multiple disease populations, potentially amortizing media investment over a much larger commercial base.
That may be particularly important for a company trying to challenge larger immunology franchises.
Market Implications
UCB: is moving Bimzelx from specialty-drug launch toward a scaled global immunology franchise.
AbbVie and J&J: competitive pressure increasingly includes patient activation and media intensity, not only clinical data.
Streaming platforms: are becoming part of pharmaceutical commercial infrastructure as measurement expands beyond linear TV.
Investors: advertising growth should be judged alongside prescription growth, payer access and persistence — not as a standalone signal of commercial success.
ANALYTICAL MATRIX
| Dimension | Current Signal | Opportunity | Key Risk |
| Media investment | US$56.9m/month | Accelerate awareness | Diminishing returns |
| Streaming | 53.85% of spend | Better targeting | Measurement fragmentation |
| Indication breadth | Multiple immune diseases | Lower acquisition cost per patient | Brand dilution |
| Commercial growth | €1.53bn H1 2026 | ≥€7bn peak-sales ambition | Crowded category |
| Competition | Skyrizi/Rinvoq/Tremfya | Share capture | Payer friction |
Bimzelx is not merely buying advertising. UCB is buying speed.
In immunology, where several therapies can offer strong efficacy, the competitive advantage increasingly belongs to the company that converts evidence into awareness, access and persistence most efficiently.
And when streaming becomes the largest component of media spending for a rapidly scaling specialty drug, the broader signal is clear:
pharmaceutical marketing is moving from broadcast medicine toward algorithmic demand generation.